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Abstract (260 words) 122 
Background: There is uncertainty about the impact of SARS-CoV-2 infection in individuals with 123 
rare inborn errors of immunity (IEI), a population at risk of developing severe COVID-19. This is 124 
relevant not only for these patients but also the general population, as studies of IEIs can unveil 125 
key requirements for host defense. 126 
Objective: Describe the presentation, manifestations and outcome of SARS-CoV-2 infection in 127 
IEI to inform physicians and enhance understanding of host defense against SARS-CoV-2.  128 
Methods: An invitation to participate in a retrospective study was distributed globally to 129 
scientific, medical and patient societies involved in the care and advocacy for patients with IEI.  130 
Results: We gathered information on 94 IEI patients with SARS-CoV-2 infection. Median age 131 
was 25-34 years. 53 patients (56%) suffered from primary antibody deficiency, 9 (9.6%) had 132 
immune dysregulation syndrome, 6 (6.4%) a phagocyte defect, 7 (7.4%) auto-inflammatory 133 
disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defect, and 2 (2%) 134 
bone marrow failure. Ten were asymptomatic, 25 were treated as outpatients, 28 required 135 
admission without intensive care or ventilation, 13 required non-invasive ventilation or oxygen 136 
administration, 18 were admitted to intensive care units, 12 requiring invasive ventilation, and 3 137 
extra corporeal membrane oxygenation. Nine patients (seven adults, two children) died. 138 
Conclusions: This study demonstrates that (1) >30% of IEI patients had mild COVID19, and 139 
(2) risk factors predisposing to severe disease/mortality in the general population also seemed  140 
to affect IEI patients, including more younger patients. Further studies will identify pathways that 141 
are associated with increased risk of severe disease and are non-redundant or redundant for 142 
protection against SARS-CoV-2.  143 
 144 
Clinical Implications: Risk factors predisposing to severe disease and mortality following 145 
SARS-CoV-2 infection in patients with IEI were similar to the general population. 146 
Notwithstanding inclusion and diagnostic bias, admission rates to ICU tended to be higher and 147 
median age of affected patients lower than in the general population. 148 
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 149 
Capsule Summary: Clinical data from 94 SARS-CoV-2-infected individuals affected by inborn 150 
errors of immunity provide initial insights into the requirements and redundancies of immune 151 
pathways in host defense against and severity of SARS-CoV-2 infection. 152 
 153 
Keywords: SARS CoV2, COVID19, primary immunodeficiencies, inborn errors of immunity; 154 
hypogammaglobulinemia; immune dysregulation 155 
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Introduction 167 
In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a 168 
single stranded RNA virus, emerged in the Hubei province of China as a novel human 169 
pathogen. SARS-CoV-2 causes an infectious disease (COVID-19) characterized by pneumonia 170 
and acute respiratory failure1-4. SARS-CoV-2 infects human cells by binding to the angiotensin 171 
converting enzyme 2 (ACE2), which is expressed predominantly by lung and intestinal epithelial 172 
cells, alveolar cells, and vascular endothelial cells. SARS-CoV-2 spreads within the human 173 
population mainly via droplet transmission and has infected >29 million individuals, causing 174 
>930, 000 deaths. There is a broad clinical spectrum including asymptomatic infection, mild 175 
infection (fever, fatigue, diarrhea, vomiting, myalgia, dry cough, dyspnea and pneumonia) 176 
respiratory failure, myocarditis, thromboembolism and finally fatal multi-organ failure5, 6. The 177 
pathophysiology of COVID-19 results from direct cytopathic effects of SARS-CoV-2 on 178 
respiratory epithelia, endothelia and other organ-specific cell types, and subsequent induction 179 
of a pro-inflammatory cytokine storm and dysregulated adaptive immunity causing severe tissue 180 
damage7.  181 
 182 
Current epidemiology studies indicate the case fatality rate of SARS-CoV-2 infection ranges 183 
from 1-20%, while the infection fatality rate is 0.2-1.3%8, 9. Despite this variability, the lethality of 184 
SARS-CoV-2 infection consistently and dramatically increases with each decade of life beyond 185 
50 years of age10 (Table 1). Furthermore, pre-existing co-morbidities (chronic lung/heart 186 
disease, obesity, diabetes, hypertension) have been reported to contribute to a more severe 187 
course of COVID-1911, 12. Importantly, the occurrence of a multisystemic hyperinflammatory 188 
syndrome in children (MIS-C) has challenged the perception of that SARS-CoV-2 infection is 189 
mild in young individuals13, 14. In most countries more males have presented with symptomatic 190 
SARS-CoV-2 infection than females, indicating gender can influence disease course and/or 191 
outcome10.  192 
 193 
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Another contributor to interindividual susceptibility to severe COVID-19 and outcome post-194 
infection is genetic heterogeneity15. This reflects the discoveries of patients with inborn errors of 195 
immunity (IEI) who exhibit increased susceptibility to pathogen infection16, 17. While >430 196 
monogenic IEIs have been described16-18, the consequences of SARS-CoV-2 infection has only 197 
been reported for a few individuals with these conditions19-22.  198 
 199 
Thus, the aim of this multicenter, retrospective international study was to assess the impact of 200 
SARS-CoV-2 infection on patients with IEIs, thereby providing a first comprehensive description 201 
on the susceptibility of an at-risk population of patients to SARS-CoV-2 infection, as well as 202 
their COVID-19 clinical course, severity, complications and outcomes. This extensive global 203 
dataset represents an important reference for clinicians treating and managing IEIs patients in 204 
the context of the COVID-19 pandemic. 205 
 206 
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Methods 208 
A retrospective study was undertaken by a web-based survey, approved by the University 209 
Hospitals Leuven Committee for Medical Ethics. The questionnaire inquired about demographic 210 
data, COVID-19 presentation, treatment and outcomes in patients with IEIs (according to 211 
current diagnostic guidelines) and documented SARS-CoV-2 infection. No identifying 212 
information was required, while physicians were given the option of providing their contact 213 
details. The survey opened on March 16th 2020 and closed on June 30th 2020. An invitation to 214 
participate in the survey was shared with members of various societies (European Society for 215 
Immunodeficiencies; Clinical Immunology Society; Latin American Society for 216 
Immunodeficiencies; African Society for Immunodeficiencies; Asia Pacific Society for 217 
Immunodeficiencies; Australasian Society for Clinical Immunology & Allergy), as well as via the 218 
International Patient Organization for Primary Immunodeficiencies, the Jeffrey Modell 219 
Foundation and the International Union of Immunological Societies (IUIS) Committee for Inborn 220 
Errors of Immunity, with the aid of social media alerts. Fisher’s exact test of independence and 221 
Bayesian analysis of contingency tables were used to calculate the statistical significance of the 222 
correlation between categorical variables. 223 
 224 
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Results 226 
Patients: 94 patients with an underlying primary immunodeficiency (PID)/IEI and infected by 227 
SARS-CoV-2, as determined by serology (n=8) or diagnostic PCR (n=86), were reported (Table 228 
1, 2). Male to female ratio was 1.8 to 1. Thirty-two patients were younger than 18 years and 62 229 
were adults (median age group 25-34 years). Eleven patients have been reported previously19-230 
21, 23
. 231 
 232 
Types and Causes of Inborn Errors of Immunity 233 
The distribution of patients according to IEI groups is shown in Figure 1. Most patients had a 234 
pre-existing primary antibody (Ab) deficiency (53/94; 56%), including: 235 
• 6 with XLA due to BTK variants (P18, P44, P50, P54, P57, P58); 236 
• 2 patients with heterozygous NFKB1 (P53, P60) or NFKB2 (P10, P13) variants; 237 
• 1 patient with X linked severe combined immune deficiency (X-SCID) who underwent gene 238 
therapy 19 years earlier that corrected his T cells but not B cells thereby remaining Ab deficient 239 
(P43); 240 
• 2 cases of autosomal recessive (AR) agammaglobulinemia (P11, P64)( Figure 1, Table 2). 241 
 242 
There were also 29 patients with common variable immune deficiency (CVID), and 2 patients 243 
with syndromic features (P1: cardiomyopathy, neutropenia; P41: ventricular septum defect, 244 
CD4+ T cell lymphopenia; Table 2). 46 of 53 Ab deficient patients received immunoglobulin (Ig) 245 
substitution as standard therapy, and 6 received immunosuppressive therapy.  246 
 247 
Six patients had phagocyte defects: 4 with X-linked (variants in CYBB [P8, P88, P92) or 248 
recessive (bialleic variants in NCF2 [P89]) chronic granulomatous disease (CGD); one (P88) 249 
was treated with cyclosporin (Figure1, Table 2). 14 patients had combined immunodeficiencies 250 
(CID), including 10 with syndromic features: Di George syndrome [P27]; trisomy 21 (Down 251 
syndrome, [P15, P17, P26])24, 25, Wiskott-Aldrich syndrome (WAS) (P16: 3 months post 252 
hematopoietic stem cell transplantation [HSCT]; P35: 5 months post-gene therapy), ARPC1B 253 
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deficiency (P25), hyper IgE syndrome due to heterozygous dominant negative variants in 254 
STAT3 (P77, P78) or biallelic variants in PGM3 (P76). Other patients had pathogenic biallelic 255 
variants in ZAP70 (P73) or IFNGR2 (P38), or heterozygous gain-of-function (GOF) variant in 256 
STAT1 (P93). P7 had chronic mucocutaneous candidiasis and recurrent pyogenic sepsis, 257 
suggesting an underlying innate immune defect. Nine patients presented with an immune 258 
dysregulation syndrome: autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 259 
(APECED, due to biallelic AIRE variants [P87]); LRBA deficiency (P86); CTLA4 260 
haploinsufficiency (P31, [post-HSCT, poor graft function], P32); autoimmune 261 
lymphoproliferation due to pathogenic variants in PRKCD (biallelic; P84), or XIAP (P9, 4 months 262 
post-HSCT); autoimmune lymphoproliferative syndrome (ALPS)-like disease (P36, P85); and 263 
prolidase deficiency due to biallelic pathogenic variants in PEPD (P30) (Figure 1, Table 2). The 264 
LRBA-deficient, PRKCD-deficient, XIAP-deficient, ALPS-like, PEPD-deficient and one of the 265 
CTLA4-deficient patients (P32) received immunosuppressive treatment (abatacept [n=2], 266 
mycophenolate [n=1], steroids [n=3], sirolimus [n=2], everolimus [n=1]) (Table 2).  267 
 268 
Seven additional patients suffered from an auto-inflammatory disease (Figure 1, Table 2):  269 
• Aicardi-Goutieres syndrome (AGS) due to biallelic RNASEH2B variants (P81, P82), treated 270 
with Ig substitution and JAK inhibitors, or homozygous SAMHD1 pathogenic variants (P83);  271 
• familial Mediterranean fever (MEFV variant [P28, P79, P80]), treated with anakinra, 272 
canakinumab and/or colchicine;  273 
• an auto-inflammatory condition with lymphopenia and autoimmune hemolytic anemia (AIHA), 274 
treated with steroids (P29]).  275 
 276 
One patient suffered from bone marrow failure caused by biallelic DNAJC21 deficiency (P36) 277 
and one had pancytopenia due to a heterozygous GATA2 variant (P94) (Figure 1, Table 2).  278 
 279 
Prior to infection, all patients were stable on standard of care treatment and 2 were on ACE-280 
inhibitor therapy. The most frequent presenting symptoms were fever (69%) and cough (47%), 281 
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followed by upper respiratory symptoms (runny nose, sneezing: 19%) and shortness of 282 
breath/dyspnea (13%). Gastrointestinal symptoms (diarrhea, vomiting) and myalgia were 283 
reported in 14% and 16% of patients, respectively, while acute respiratory insufficiency was the 284 
presenting feature in 11% of patients. Other reported symptoms were fatigue, sore throat, 285 
anosmia/ageusia, collapse, pallor and anemia.  286 
 287 
Clinical features of SARS-CoV-2+ patients with inborn errors of immunity 288 
10 (11%) patients were asymptomatic (ALPS-like [P85], AGS [P81, P82], STAT1 GOF [P93], 289 
WAS [P35], AR CGD [P89], XLA [P56], AR agammaglobulinemia [P64], 290 
hypogammaglobulinemia [P40], CID [P74]), including 4 who had pre-existing lung disease 291 
(Table 2). In these cases, testing for SARS-CoV-2 was only performed to enable travel, elective 292 
treatment, or due to positivity of a symptomatic relative/close contact.  293 
 294 
Twenty-four patients had mild disease and were treated as outpatients (Table 2). Two were 3-295 
12 years old, one was 19-24 years, six were 25-34 years, five were 35-44 years, three were 45-296 
54 years, two were 55-64 years, four were 65-74 years, and one was > 75 years. These 297 
patients included: 298 
• 14 with predominantly Ab deficiency (11 with CVID, of whom 7 had one or more 299 
comorbidities); • 1 X-SCID patient with persistent defective B cell function post gene therapy; 300 
• 1 with activated PI3 kinase syndrome (P51, PIK3R1 mutation); 301 
• 1 with CID with multiple autoimmune features (P75); 302 
• 3 with hyper-IgE syndrome due to PGM3 deficiency (P76), or STAT3 loss-of function (P77, 303 
P78) including one with chronic lung disease; 304 
• 2 with MEFV mutations (P79, P80), 1 with AGS (P83, SAMHD1 mutation), 1 with CGD due to 305 
CYBB mutation (P92), and 1 with an unspecified phagocyte defect (P90).  306 
 307 
Fifty-nine patients (63%) required hospitalization. Clinical progression of 29 of these 59 patients 308 
evolved into respiratory insufficiency (49% of hospitalized, 31% of all patients). Thirteen 309 
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patients required non-invasive ventilation/oxygen administration, and 15 (11 males, 4 females; 310 
16% of all patients) were admitted to intensive care units (ICU) for invasive ventilation, including 311 
extracorporeal membrane oxygenation (ECMO; 3 males patients, 2 succumbed, see below). 312 
Additionally, individual patients were admitted to ICU for severe AIHA (P36), hypotension (P94), 313 
or MIS-C and miliary Mycobacterium avium infection (P38; IFNGR2) but no respiratory 314 
complications. Among female patients admitted to ICU for respiratory insufficiency, two had 315 
CVID and were aged 55-64 years (P3, P4), one was >75 years (hypogammaglobulinemia; P5), 316 
and one was <2 years with trisomy 21 and chronic invasive ventilation via tracheostomy in the 317 
context of congenital heart disease (P17). In contrast, the age distribution of the 11 affected 318 
males admitted to ICU was broader than for females, and the general population (Table 1, 2):  319 
• 1 aged 0-2 years (P8 [X-CGD]);  320 
• 2 aged 3-12 years (P15 [trisomy 21]; P16 [WAS]);  321 
• 2 aged13-18 years (P13 [NFKB2]; P9 [XIAP]);  322 
• 3 aged 35-44 years (P10 [NFKB2]; P17 [agammaglobulinemia]; P1 [syndromic primary Ab 323 
deficiency]);  324 
• P14, aged 45-54 years, and P12, aged 55-64 years, both with CVID;  325 
• 1 aged ≥75 years (P6 [IgG2/IgA deficiency]).  326 
 327 
The three patients with trisomy 21 experienced acute respiratory insufficiency, requiring 328 
invasive [P15, P17] or non-invasive [P26] ventilation. P15 and P17 also had a pre-existing heart 329 
condition; P17 required a tracheostomy and chronic ventilation. Overall, 73% (11/15) of the 330 
patients needing invasive ventilation had pre-existing comorbidities (Figure 1, Table 2). 331 
 332 
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Complications and mortality due to SARS-CoV-2 infection 334 
Reported complications, as defined according to international guidelines26, 27 or current 335 
practice13, 14, were bacterial pneumonia (n=6), hemophagocytic lymphohistiocytosis (HLH) 336 
(n=6), sepsis (n=6; 7%), MIS-C (P38, IFNGR2, 1%), and kidney failure (n=5; 5%). Two patients 337 
had sepsis and HLH. Furthermore, individual patients developed AIHA, thrombocytopenia, 338 
hyporegenerative anemia, neutropenia, myocarditis, and heart failure.  339 
 340 
Nine patients in this cohort (seven adults, two children, 10%) died (Figure 1, Table 2): 4 males 341 
(0-2 years: n=1; 13-18 years: n=1; 35-44 years: n=1; >75 years: n=1), 5 females (35-44 years: 342 
n=1; 55-64 years: n=2 ; ≥75 years: n=2). The child aged 0-2 years (P8, Table 2) had X-CGD, 343 
concomitant Burkholderia sepsis and HLH. The other child (P9, 13-18 years) had severe gut 344 
graft-versus-host-disease following HSCT for XIAP deficiency and developed septic shock and 345 
HLH. Thus, it is unclear how much SARS-CoV2 infection contributed to the death in both 346 
children. P1 (male, 35-44 years) suffered a syndromic disease with congenital dysmorphisms, 347 
mild developmental delay, hypogammaglobulinemia, neutropenia, hypertrophic 348 
cardiomyopathy, and bronchopathy. He developed pneumothorax, pulmonary hypertension and 349 
heart failure after SARS-CoV-2 infection and died despite treatment with antibiotics, Ig infusion, 350 
steroids and ECMO. The other deceased patients (5 females, 1 male) suffered from Ab 351 
deficiencies (CVID [P2, P3, P4, P7]; isolated IgG deficiency P5]; IgA and IgG2 deficiency [P6]; 352 
Table 2). Most patients were treated for potential bacterial co-infection or super-infection with 353 
antibiotics and extra Ig infusion.  354 
 355 
All adult PID patients who succumbed to SARS CoV-2 infection had pre-existing comorbidities 356 
(Figure 1, Table 2): P1 had cardiomyopathy and developed pulmonary hypertension and heart 357 
failure; P2 had chronic kidney disease, underwent kidney transplant and had several 358 
malignancies; all other patients were above 55y old and P3 had chronic lung and heart disease; 359 
P4 had chronic lung disease and developed sepsis; P5 had chronic lung, heart and kidney 360 
disease, hypertension and diabetes; P6 had diabetes; P7 had lymphoproliferative disease, 361 
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gastrointestinal disease and genital tract neoplasm and developed Enterococcus faecium 362 
sepsis. P2, P3, P5, P6 and P7 all developed hypotension and kidney failure during COVID-19. 363 
However, exact cause of COVID19-related deaths for these patients is unknown. 364 
 365 
Treatments of SARS-CoV-2 infection in IEI patients 366 
Therapeutic strategies varied greatly and consisted of the following medications, alone or in 367 
combination: antibiotics (51%), Ig replacement (10.6%), hydroxychloroquine/ chloroquine 368 
(33%), systemic steroids (21%), monoclonal Abs (8.5%, tocilizumab [n=6], anakinra [n=1]), 369 
antivirals (lopinavir and ritonavir 12.7%, remdesivir 9.6%, favipravir 1%), enoxaparin (12.7%). 370 
Five patients (two in ICU) received convalescent plasma and other treatments (antibiotics, 371 
chloroquine, remdesivir, steroids, enoxaparin, tocilizumab), with four surviving. Six patients 372 
were treated with tocilizumab, 4 in ICU, 1 of whom died of infection. (Hydroxy)chloroquine was 373 
administered to 31 patients (5 succumbed), and remdesivir to 9 patients, 5 of whom required 374 
admission to ICU and invasive ventilation, all of whom survived. 375 
 376 
The association between outcome (alive/dead) and the onset of respiratory insufficiency, the 377 
presence of comorbidities or the sex of the patient was not significantly different between 378 
patients who survived or patients who succumbed to SARS-CoV2. Moreover, no correlation 379 
could be found between outcome and respiratory insufficiency, age groups or PID type. 380 
Individual patient categories were too small to allow for multivariate analysis. 381 
 382 
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Discussion 384 
Individuals with IEIs, and subsequent immune deficiency or immune dysregulation, are a priori 385 
considered an at-risk population for developing severe COVID-19 following SARS-CoV2 386 
infection. While a few studies have reported outcomes of SARS-CoV2 infection in small 387 
numbers of PID patients19-22, the impact of the COVID-19 pandemic on the broader global 388 
population of these patients has not been established. Here, we report the occurrence and 389 
course of SARS-CoV-2 infection in 94 patients with IEI. Distribution between diagnostic IEI 390 
categories reflected that of large patient registries (esidregistry.org; usidnet.org). Thus, patients 391 
with Ab deficiencies are the predominant group with COVID, and ~20% of patients had CIDs or 392 
impaired innate immunity (Figure 1).  393 
 394 
Overall, presentation and risk factors (e.g. pre-existing heart, lung or kidney disease) for severe 395 
COVID-19 in IEI patients seem very similar to those in the general population. Case fatality rate 396 
was ~10%, in line with global data from the general population (1-20%, Table 1)1, 10, 28, 29 . The 397 
mortality rate may actually be lower, as death of some patients may have resulted from the IEI, 398 
rather than SARS-CoV2 infection (eg Burkholderia infection in P8 [X-CGD]; severe GvHD in P9 399 
[XIAP-deficiency, post HSCT). Thus, perhaps surprisingly, the inherent immune-compromised 400 
state of the patients studied here was generally not a predominant risk factor for severe COVID-401 
19. Similar to some epidemiological analyses28, there was a male predominance amongst all IEI 402 
patients (1.8:1), as well as those admitted to ICU (2.8:1). The gender ratio among CVID 403 
patients with a more severe course (requiring at least oxygen) was also strongly skewed 404 
towards males (M:F - 8:5). However, there are apparent differences in age distribution of IEI 405 
patients affected by SARS-CoV2 (median: 25-34 years) as well as the frequency of ICU 406 
admissions (16%) compared to the general population (Table 1)10. Our study suggests younger 407 
male patients with IEI are more likely to endure severe COVID-19 and require ICU admission. 408 
This skewing is not explained by the inclusion of X-linked disorders in this cohort (n=13). 409 
Rather, differential levels of inflammatory mediators, T cell responses and/or virus-specific Abs 410 
Jo
urn
al 
Pr
e-p
roo
f
Page 17 of 36 
between infected males and females may explain the predominance of males with severe 411 
COVID-1930.  412 
 413 
One of the key findings from our study is the identification of both redundancies in the human 414 
immune system for host defense against SARS-CoV2, and putative mediators of immune 415 
pathology following viral infection. First, many patients with defects predominantly in the 416 
adaptive immune system (eg defective humoral [XLA, agammaglobulinemia, persisting humoral 417 
immunodeficiency in X-SCID post gene therapy] and/or T cell [ZAP70, PGM3, STAT3, ARPC1B 418 
mutations] responses) were either asymptomatic or had only mild disease and promptly 419 
recovered (Table 2, refs19-22). Similarly, 11 CVID patients had mild disease and did not require 420 
hospital admission, despite several having comorbidities. Thus, certain components of adaptive 421 
immunity do not appear to be essential for controlling SARS-CoV2 infection. Rather, these 422 
adaptive immune deficiencies may even contribute to a milder course by reducing the immune-423 
mediated sequelae. This is consistent with findings that patients with IEIs that specifically affect 424 
B and T cell development or function do not exhibit increased susceptibility to severe disease 425 
caused by influenza infection31, 32. Our findings that CVID patients comprised a large proportion 426 
of our cohort (>30%), and that 4 of these patients died (45% of all deaths), may infer that intact 427 
humoral immunity is important for host defense against SARS-CoV2. However, these patients 428 
were generally older than the rest of the cohort (median age range 45-54 years), and many had 429 
pre-existing health conditions that predispose to severe COVID-19 in the general population 430 
(lung disease in ~50%, kidney/heart/gut/liver disease in ~20%, Table 2).  431 
 432 
Second, with the exception of the X-CGD patient with Burkholderia sepsis, the other 3 CGD 433 
patients had relatively mild disease, suggesting a modest contribution of neutrophil function in 434 
anti-SARS-CoV2 immunity. 435 
 436 
Third, mild or asymptomatic disease in SARS-CoV-2+ patients with dominant negative STAT3 437 
variants, despite pre-existing chronic lung disease, suggest STAT3 signaling contributes to the 438 
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cytokine storm characteristic of severe COVID-19. Together with findings that serum IL-6 levels 439 
are greatly increased during SARS-CoV-2 infection6, 33-35, and predict mortality in severe 440 
COVID-1936, 37, our data suggest that IL-6/STAT3 contributes to the inflammatory response and 441 
subsequent disease severity in COVID-19. Based on this, mild disease in XLA may reflect not 442 
only B-cell deficiency but also impaired IL-6 production by BTK-deficient myeloid cells38, 443 
potentially ameliorating SARS-CoV-2-induced cytokine storm.  444 
 445 
Fourth, all patients with auto-inflammatory diseases were asymptomatic or stayed at home. 446 
However, most of these patients were young children, and both adults were treated with IL-1 447 
blockade and colchicine. 448 
 449 
Two recent studies provide convincing evidence that the disruption of type I interferon signaling 450 
is a frequent cause of life-threatening COVID19 (refs 39-40). In the first study, 650 patients with 451 
life-threatening COVID19 were studied by whole exome sequencing under the hypothesis that 452 
severe COVID19 is allelic with severe influenza (39) or that genes biologically related to these 453 
loci would be involved (31,32). Indeed, 3,5% of patients had known (AR IRF7 and IFNAR1 454 
deficiency, autosomal dominant TLR3, TICAM1, TBK1 and IRF3 deficiency) and new 455 
(autosomal dominant UNC93B1, IRF7, IFNAR1, IFNAR2 deficiency) genetic defects abolishing 456 
induction or amplification of type I IFNs (39).  In the second study, neutralizing auto-antibodies 457 
against type I IFNs were found in 10.2% of 987 patients with life-threatening COVID-19 458 
pneumonia, resulting in low or undetectable serum levels of IFN-α during acute disease. 94% of 459 
the patients with auto-antibodies were male. The net result of both the anti-IFN autoAbs and the 460 
loss of function variants in crucial type I IFN pathway genes is a profound defect in type I IFN 461 
immunity, underlying life-threatening COVID19 pneumonia.  462 
 463 
Intriguingly we observed mild disease in patients with interferonopathies (AGS) treated with 464 
JAK-inhibitors, suggesting sufficient residual type I IFN to protect from severe initial infection. It 465 
was striking that patients with NFKB1 or NFKB2 mutations required hospitalization, with both 466 
NFKB2-deficient individuals being admitted to ICU (Table 2). As the canonical and alternate 467 
NFKB pathways are activated in plasmacytoid DCs to produce large amounts of type 1 IFNs41, 468 
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severe COVID19 in patients with NFKB1 or NFKB2 loss of function variants may be explained 469 
by deficient type I IFN responses. Similarly, an absence of type 1 IFN-producing myeloid cells 470 
may underlie COVID-19 due to GATA2 haploinsufficiency (Table 1)42. Since auto-immunity is 471 
a frequent manifestation of CVID, it can be hypothesized that the presence or 472 
absence of anti-type I IFN autoantibodies predisposed CVID patients to either life-473 
threatening or mild disease following SARS-CoV2 infection. The finding of neutralizing 474 
anti-IFN autoantibodies in some individuals with severe COVID-1940 may also explain why 475 
agammaglobulinemia patients generally did not develop severe COVID-19, and predict that 476 
COVID-19 may occur in some AIRE-deficient patient since these patients produce autoAbs 477 
against type 1 IFNs43. Moving forward, it will be important to not only study functionality of 478 
immune cells from patients with IEI in the context of innate IFN signaling, but also assess these 479 
patients for neutralizing anti-type 1 IFN Abs.  480 
 481 
Several caveats of our study need to be recognized. First, asymptomatic or mildly symptomatic 482 
SARS-CoV-2-infected IEI patients are likely to be underdiagnosed, mainly due to regional 483 
testing priorities contributing to an ascertainment bias of such a retrospective study. Second, as 484 
we were guided by the most recent update of IEI16-18, it is unlikely that all IEI patients who have 485 
been infected with SARS-CoV-2 were captured by our survey. Indeed, the field of IEI continues 486 
to grow rapidly, with >30 novel genetic defects having been described since the last update by 487 
the IUIS committee. Thus, we have not considered SARS-CoV2 infection in individuals with 488 
these putative novel monogenic causes of immune dysregulation. Third, if our survey accurately 489 
reflects the true incidence of COVID-19 in IEI, it suggests immunodeficient patients have been 490 
less frequently infected and are less symptomatic than the general population. This could be 491 
explained by IEI patients being informed early in the pandemic about safety measures by 492 
patient and scientific organizations. Moreover, IEI patients are familiar with frequent sanitation 493 
practices, avoiding crowds, physical distancing, self-isolation etc., as recommended during this 494 
pandemic. Fourth, our study does not include any patients with known defects of type I IFN 495 
pathways. Based on findings from studies of severe influenza31, 32, and recent investigation of 496 
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the genetics of life-threatening SARS-CoV2 infection39, these patients are even more strongly 497 
advised to practice strict hand hygiene, mask wearing and social distancing than other PID 498 
patients.  499 
 500 
In conclusion, we report the course of COVID-19 in 94 patients with IEI. The survey revealed 501 
that a substantial subgroup of IEI patients suffer only a mild course of disease. Risk factors 502 
predisposing to severe disease and mortality amongst IEI patients were comparable to the 503 
general population. However, younger IEI patients were more severely affected and more 504 
frequently admitted to ICU compared to the general population. These findings warrant 505 
recommendation for further stringent personal protective measures for patients affected by IEI. 506 
The urgent need to document the impact of SARS-CoV-2 on patients with defined IEIs is 507 
currently being met by registries developed by additional organizations (e.g. ESID registry, 508 
ERN-RITA joint effort, COPID19), as well as the COVID Human Genetic Effort which is 509 
performing large-scale genetic and functional studies on patients affected by severe 510 
COVID1915, 39, 40. Ideally, these studies will also include prospective longitudinal analysis to 511 
determine the long-term impact of SARS-CoV2 even in convalescent individuals. These 512 
initiatives will further our insight into susceptibility of individual IEI patients to disease. This will 513 
not only reveal necessary and redundant pathways for host defense against SARS-CoV-2, but 514 
also identify those that mediate collateral tissue damage in response to viral infection. 515 
Collectively, this and future studies have the potential to provide opportunities for immune 516 
modulation to treat COVID-19 in IEI patients as well as the general population.  517 
  518 
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Figure 1. Distribution of patients based on IEI category, co-morbidities and outcome 635 
Shaded colors indicate patients who succumbed with COVID-19 in that IEI group. The numbers 636 
of patients (Alive and Deceased) are indicated for each individual sub-category on the figure.  637 
A: ambulatory; H: hospitalized; ICU: intensive care unit; NIV/O2: non-invasive 638 
ventilation/oxygen; “+”: with co-morbidities; “-”: no co-morbidities. 639 
 640 
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Table 1: Age distribution and lethality of SARS-CoV-2 infection in patients with inborn errors of immunity. 
Patients with inborn errors of immunity General Population 
Age 
groups 
(94 cases) 
M:F COVID-19 cases per age 
group in our cohort 
N (%) 
Deaths in our 
cohort 
N (%) 
ICU 
admission 
N (%) 
Age groups 
general pop 
COVID-19 cases 
per age group 
(general pop %) 
Deaths 
(general 
pop) % 
ICU admission 
(general pop) % 
0-2 yrs 6:1 7 (7.4%) 1/7 (14%) 3/7 (43%) 0-9 yrs 
 
1.5A 4.2B 0.1A  0C  0.7 A 
3-12 yrs 12:5 17 (18%) 0/17 2/17 (12%) 
13-18 yrs 4:4 8 (8.5%) 1/8 (10%) 4/8 (50%) 10-19 yrs 3.7 7.8 0.1 0.2 0.4 
19-24 yrs 4:0 4 (4.2%) 0/4 0/4 20-29 yrs 13.8 20.0 0.1 0.2 0.5 
25-34 yrs 10:3 13 (13.8%) 0/13  0/13 30-39 yrs 16.3 17.8 0.4 0.2 0.9 
35-44 yrs 9:6 15 (16%) 2/15 (13%) 3/15 (20%) 40-49 yrs 16.6 14.4 1.0 0.3 1.5 
45-54 yrs 8:1 9 (9.5%) 0/0 1/9 (11%) 50-59 yrs 17.9 12.7 2.4 0.8 2.5 
55-64 yrs 5:5 10 (10.6%) 2/10 (20%) 3/10 (30%) 60-69 yrs 13.6 7.6 6.7 2.7 4.1 
65-74 yrs 0:5 5 (5.3%) 0 0 70-79 yrs 8.0 5.3 16.6 8.0 5.6 
>75 yrs 2:3 5 (5.3%) 3 (60%) 2 (40%) >80 yrs 8.7 10.0 28.7 16.0 3.6 
All patients 65:35 
(1.8:1) 
NA 10 (10%) 20 (20%) All   5.4% 
(1-20%) 
2.3% 
 
F: female; ICU: intensive care unit; M: male; N: absolute number; pop: population; yrs: years. Data for the general population are all taken from ref 10. 
A: data from US, n=1 320 488 cases [ref 10] 
B: A: data from UK, n=73 359 cases (https://www.gov.uk/government/publications/demographic-data-for-coronavirus-testing-england-28-may-to-26-august/demographic-
data-for-coronavirus-covid-19-testing-england-28-may-to-26-august) 
C: https://ourworldindata.org/covid-deaths; average of data from Spain, Italy, China and South Korea 
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Table 2. Summary of patients’ characteristics 1 
 2 
Pt
n. 
Outco
me 
PID Age 
group 
(yrs) 
Ge
nd
er 
Co-
morbidities 
Usual 
therapy 
Manifestations Respiratory 
insufficienc
y 
Invasive 
ventilatio
n 
Severity Complica
tions 
Therapy Cou
ntry 
Seroco
nversi
on 
Estimated 
duration of 
SARS-CoV-
2 PCR 
positivity 
Duration of 
infection/ 
symptoms Fe
ve
r 
Co
ug
h 
UR
S 
G
I 
My
alg
ia 
Other 
1 
Deceas
ed 
Ab def. 
Syndromi
c 
presentati
on 
35-44 M 
Neutropenia, 
dysmorphism, 
developmental 
delay, 
hypertrophic 
cardiomyopat
hy 
Ig, G-CSF X X    
Chest 
pain 
X ECMO 
ICU 
admission 
Pneumot
horax, 
pulmonar
y 
hypertens
ion, heart 
failure 
Antibiotics, 
steroids, Ig 
Fran
ce 
   
2 
Deceas
ed 
Ab def. 
CVID 
35-44 F 
Kidney tx, 
lymphoma 
and cervical 
cancer in 
remission 
Ig, steroids      
Hypotensi
on, renal 
failure 
  
Hospital 
admission 
Renal 
failure 
Antibiotics, 
chloroquine, 
enoxaparin, 
conv. plasma 
USA    
3 
Deceas
ed 
Ab def. 
CVID 
55-64 F 
Lung disease, 
heart disease, 
ITP 
Ig, rituximab, 
metoprolol 
X X    
Dyspnea, 
fatigue, 
hypotensi
on, renal 
failure 
X X 
ICU 
admission 
Renal 
failure 
Antibiotics, 
chloroquine, 
enoxaparin 
USA    
4 
Deceas
ed 
Ab def. 
CVID 
55-64 F Lung disease Ig X X     X X 
ICU 
admission 
Sepsis 
Antibiotics, 
steroids, 
tocilizumab, 
lopinavir, 
ritonavir 
Italy No 
17 days 
(until death) 
17 days 
(until death) 
5 
Deceas
ed 
Ab def. 
IgG 
deficiency 
≥75 F 
Lung disease, 
heart disease, 
kidney 
disease, 
hypertension, 
diabetes 
Ig X X    
Dyspnea, 
hypotensi
on, renal 
failure 
X X 
ICU 
admission 
Renal 
failure 
Antibiotics, 
chloroquine, 
enoxaparin 
USA    
6 
Deceas
ed 
Ab def. 
IgG2 and 
IgA 
deficiency 
≥75 M 
Diabetes, 
AIHA 
Ig X     
Hypotensi
on, renal 
failure 
X X 
ICU 
admission 
Renal 
failure 
Antibiotics, 
chloroquine, 
enoxaparin 
USA    
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7 
Deceas
ed 
Ab def. 
CVID 
≥75 F 
Lymphoprolife
rative disease, 
GI disease, 
genital tract 
neoplasm  
Ig      
Acute 
confusion
al 
syndrome 
  
Hospital 
admission 
E. 
faecium 
sepsis, 
renal 
failure 
Antibiotics, 
chloroquine 
Spai
n 
   
8 
Deceas
ed 
Phagocyt
e defects 
CGD 
(CYBB) 
0-2 M - - X     
Burkholde
ria sepsis 
X ECMO 
ICU 
admission 
HLH 
Antibiotics, 
steroids 
Fran
ce 
   
9 
Deceas
ed 
Immune 
dysregula
tion 
disorder 
(XIAP) 
13-18 M 
4 months 
post-HSCT, 
severe gut 
GVHD 
Antibiotics, 
antifungals, Ig, 
steroids, 
cyclosporine 
X     Collapse X X 
ICU 
admission 
Sepsis, 
HLH 
Antibiotics, Ig Chile    
10 
Resolv
ed 
Ab def. 
CVID 
(NFKB2) 
35-44 M - 
Ig, antibiotics, 
antivirals, 
mAb 
X X X    X X 
ICU 
admission 
Bacterial 
pneumoni
a 
Antibiotics, Ig, 
hydroxychloro
quine, 
remdesivir, 
lopinavir, 
ritonavir, 
tocilizumab 
Italy    
11 
Resolv
ed 
Ab def. 
Agamma-
globuline
mia 
35-44 M Lung disease 
Ig, steroids, 
antibiotics, 
GM-CSF 
X X   X  X ECMO 
ICU 
admission 
HLH 
Antibiotics, 
steroids, 
chloroquine, 
GM-CSF, 
conv. plasma 
Belgi
um 
 60-75 days 50 days 
12 
Resolv
ed 
Ab def. 
CVID 
55-64 M Asthma 
Ig, 
immunosuppr
essive 
X X   X  X X 
ICU 
admission 
Sepsis 
(Candida) 
Antibiotics, 
chloroquine, 
remdesivir, 
lopinavir, 
ritonavir, mAb 
Italy No 4 weeks  
13 
Resolv
ed 
Ab def. 
CVID, 
(NFKB2) 
13-18 M 
Alopecia tot., 
psoriasis 
- X X X X  Dyspnea X X 
ICU 
admission 
Sepsis 
HLH 
Antibiotics, 
steroids, 
tocilizumab, 
remdesivir, 
conv. plasma 
USA Yes 8 days  
14 
Resolv
ed 
Ab def. 
CVID 
45-54 M Lung disease 
Ig, 
immunosuppr
essive 
X X     X X 
ICU 
admission 
- 
Steroids, 
chloroquine, 
tocilizumab 
remdesivir, 
lopinavir, 
Italy No 9 days  
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ritonavir 
15 
Resolv
ed 
CID 
Trisomy 
21 
3-12 M 
Lung disease, 
heart disease, 
pulmonary 
hypertension, 
mental 
disability 
Antibiotics, Ig, 
antivirals, 
steroids 
X X  X   X X 
ICU 
admission 
HLH 
Antibiotics, 
steroids, Ig, 
remdesivir 
Germ
any 
   
16 
Still in 
ICU 
CID 
Wiskott-
Aldrich 
syndrome  
3-12 M 
3 months 
post-HSCT, GI 
disease 
Antibiotics, Ig, 
steroids 
X X    
CMV 
encephali
tis, 
anosmia 
X X 
ICU 
admission 
Bacterial 
pneumoni
a 
Steroids, Ig 
Mexi
co 
   
17 
Still in 
ICU 
CID 
Trisomy 
21 
0-2 F 
Heart defect, 
tracheostomy 
with chronic 
ventilation 
Antibiotics, Ig       X X 
ICU 
admission 
- - Chile    
18 
Resolv
ed 
Ab def. 
XLA 
(BTK) 
3-12 M Spherocytosis Ig X X  X  
Dyspnea, 
chest 
pain 
X  
Admissio
n with 
O2/NIV  
Bacterial 
pneumoni
a 
Antibiotics, 
remdesivir, 
enoxaparin, 
conv. plasma 
USA    
19 
Resolv
ed 
Ab def. 
CVID 
25-34 F - Ig X X    Anosmia X  
Admissio
n with 
O2/NIV 
- 
Steroids, 
chloroquine, 
tocilizumab 
lopinavir, 
ritonavir 
Italy No 9-50 days  
20 
Resolv
ed 
Ab def. 
CVID 
25-34 M - Ig X X  X  Fatigue X  
Admissio
n with 
O2/NIV 
- 
Antibiotics, 
steroids 
Fran
ce 
No   
21 
Resolv
ed 
Ab def. 
CVID 
45-54 M Lung disease Ig, antibiotics X X     X  
Admissio
n with 
O2/NIV 
- Antibiotics, Ig 
Fran
ce 
   
22 
Resolv
ed 
Ab def. 
CVID 
45-54 M Lung disease Ig, antibiotics X  X  X  X  
Admissio
n with 
O2/NIV 
- Antibiotics 
Fran
ce 
Yes 
(IgM)  2 months 
23 
Resolv
ed 
Ab def. 
Hypo-
gamma-
globuline
mia 
45-54 F 
Diabetes, 
heart disease, 
hypertension, 
neuropathy, 
mitochondrial 
myopathy 
Ig, antibiotics, 
antifungals, 
ACE-inhibitor, 
atorvastatin, 
bisoprolol, 
eplenerone, 
metformin, 
insulin 
X X    
Neuropat
hy 
X  
Admissio
n with 
O2/NIV 
- Antbiotics UK  15 days 18 days 
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24 
Resolv
ed 
Ab def. 
CVID 
45-54 M 
Large granular 
lymphocyte 
leukemia 
Ig X X     X  
Admissio
n with 
O2/NIV 
- 
Antibiotics, 
chloroquine 
Spai
n 
Yes 30 days 17 days 
25 
Resolv
ed 
CID 
ARPC1B 
0-2 M 
Eczema, cow 
milk protein 
allergy 
Antibiotics, Ig X     Collapse X  
Admissio
n with 
O2/NIV 
- Antibiotics 
Mexi
co 
   
26 
Resolv
ed 
CID 
Trisomy 
21 
3-12 M - - X X    
Co-
infection 
with 
Mycoplas
ma 
pneumoni
ae 
X  
Admissio
n with 
O2/NIV 
Neutrope
nia 
Antibiotics 
Belgi
um 
   
27 
Resolv
ed 
CID 
DiGeorge 
syndr. 
0-2 M 
Lung disease, 
tracheostomy 
with chronic 
ventilation 
Antibiotics, Ig X      X  
Admissio
n with 
O2/NIV 
- Ig Chile    
28 
Resolv
ed 
Auto-
inflammat
ory 
disorder 
(MEFV) 
55-64 M Lung disease - X X X  X Dyspnea X  
Admissio
n with 
O2/NIV 
- 
Steroids, 
lopinavir, 
ritonavir 
Fran
ce 
   
29 
Resolv
ed 
CID with 
immune 
dys-
regulation
and auto-
inflammat
ion 
35-44 M 
Hyporegenera
tive anemia, 
AIHA, 
intermittent 
renal 
insufficiency 
Status post 
rituximab, 
steroids 
X X    
Dyspnea 
Co-
infection 
with 
CoV229E 
  
Hospital 
admission 
Anemia, 
neutropen
ia 
 
Chloroquine, 
lopinavir, 
ritonavir 
tocilizumab 
Germ
any 
Yes 42 days 13 days 
30 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
(PEPD) 
25-34 M 
Kidney 
disease, 
mental 
disability 
Steroids, 
antibiotics, 
antivirals, 
antifungals, 
mAB 
X X     X  
Admissio
n with 
O2/NIV 
Sepsis 
Antibiotics, 
steroids 
Italy    
31 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
(CTLA4) 
13-18 F 
Lung disease, 
post-HSCT 
with poor graft 
function 
Ig, antibiotics, 
antivirals, 
antifungals, 
     Dyspnea X  
Hospital 
admission 
- 
Chloroquine, 
remdesivir 
Spai
n 
   
Jo
urn
al 
Pr
e-p
roo
f
Page 30 of 36 
32 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
(CTLA4) 
25-34  
Lung disease, 
GI disease, 
chronic JCV 
cystitis 
Steroids, Ig, 
everolimus, 
abatacept 
X     
Anosmia, 
ageusia 
X  
Admissio
n with 
O2/NIV 
- 
Steroids, 
aspirin, 
remdesivir 
USA    
33 
Resolv
ed 
Ab def. 
CVID 
35-44 M Lung disease 
Antibiotics, 
antivirals 
X X   X 
Dyspnea, 
fatigue 
  
Hospital 
admission 
Bacterial 
pneumoni
a 
Antibiotics, 
lopinavir, 
ritonavir 
UK    
34 
Resolv
ed 
Ab def. 
Isolated 
IgG 
subclass 
def.  
55-64 F Lung disease 
Antibiotics, Ig, 
omalizumab 
     Dyspnea   
Hospital 
admission 
Bacterial 
pneumoni
a 
Antibiotics, 
chloroquine 
Spai
n 
   
35 
Resolv
ed 
CID 
Wiskott-
Aldrich 
syndrome  
0-2 M 
5 months post 
gene therapy  
Ig, 
prophylactic 
antivirals, 
pentamidine, 
thrombopoieti
n agonist 
     
Asympto
matic 
  
Asympto
matic 
Mild 
myocardit
is 
Chloroquine, 
lopinavir, 
ritonavir 
Italy Yes 41 days  
36 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
ALPS-like 
13-18 M 
Immune 
thrombocytop
enia 
Mycophenolat
e, 
eltrombopag 
X  X   
Anemia, 
jaundice   
Hospital 
admission 
AIHA Steroids USA    
37 
Resolv
ed 
CMC and 
recurrent 
sepsis 
0-2 M - Ig X X X      
Hospital 
admission 
Bacterial 
pneumoni
a 
Antibiotics 
Belgi
um 
   
38 
Resolv
ed 
MSMD 
IFNGR2 
deficiency 
0-2 M - - X X    
Miliary 
mycobact
erium 
avium co-
infection, 
leukocyto
sis 
  
Hospital 
admission 
Multisyste
mic 
inflammat
ory 
syndrome 
Antibiotics, 
steroids, Ig, 
anti-
mycobacterial 
antibiotics 
USA    
39 
Resolv
ed 
Bone 
marrow 
failure  
(DNAJC2
1) 
3-12 M 
Exocrine 
pancreas 
insufficiency, 
failure to 
thrive, 
cytopenias, 
bone 
Antibiotics, 
red blood cell 
transfusions 
X     
Increased 
anemia 
and 
thromboc
ytopenia 
  
Hospital 
admission 
Incomplet
e HLH 
Antibiotics 
Germ
any 
Yes 
(IgG, 
IgA) 
 7 days 
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anomalies, 
mental 
disability 
40 
Resolv
ed 
Ab def. 
Hypogam
maglobuli
nemia 
3-12 M Uveitis Ig      
Asympto
matic 
  
Asympto
matic 
- - Chile    
41 
Resolv
ed 
Ab def. 
Syndromi
c 
presentati
on 
3-12 M 
Heart defect, 
CD4+ T cell 
lymphopenia, 
mental 
disability, 
dysmorphism 
Ig  X X      
Hospital 
admission 
- - Chile    
42 
Resolv
ed 
Ab def. 
CVID 
13-18 M Lung disease Ig X   X     
Hospital 
admission 
- 
Ig, 
chloroquine 
Mexi
co 
   
43 
Resolv
ed 
Ab def. X-
SCID 
after gene 
therapy, 
residual B 
cell 
dysfunctio
n 
(IL2RG) 
19-24 M - Ig X X X X  
Anosmia, 
ageusia, 
fatigue 
  
Not 
admitted 
- Antibiotics 
Fran
ce 
   
44 
Resolv
ed 
Ab def. 
XLA 
(BTK) 
19-24 M Lung disease Ig X X    Dyspnea   
Hospital 
admission 
- 
Antibiotics, 
chloroquine, 
enoxaparin, 
conv. plasma 
USA    
45 
Resolv
ed 
Ab def. 
CVID 
25-34 M IBD Ig X X   X    
Not 
admitted 
- 
Antibiotics, 
chloroquine 
USA    
46 
Resolv
ed 
Ab def. 
CVID 
25-34 M Lung disease Ig X X X  X    NA - 
Antibiotics, 
chloroquine, 
lopinavir, 
ritonavir 
Spai
n 
   
47 
Resolv
ed 
Ab def. 
CVID 
25-34 F 
Lung disease, 
AI disease 
Ig, antibiotics X X X   Dyspnea   
Hospital 
admission 
- 
Steroids, 
chloroquine, 
enoxaparin 
Brazil No 16-35 days  
48 
Resolv
ed 
Ab def. 
CVID 
25-34 M - Ig, antibiotics      
Sore 
throat 
  
Not 
admitted 
- Antibiotics 
Arge
ntina 
 41 days  
 
49 
Resolv
ed 
Ab def. 
CVID 
25-34 M - Ig      
Anosmia, 
ageusia 
  
Not 
admitted 
- - 
Fran
ce 
Yes  2 weeks 
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50 
Resolv
ed 
Ab def. 
XLA 
(BTK) 
25-34 M - Ig X X       
Hospital 
admission 
- 
Antibiotics, 
steroids, Ig, 
chloroquine 
Italy  64 days  
51 
Resolv
ed 
Ab def. 
APDS 
(PIK3R1) 
25-34 F - Ig X     
Sore 
throat 
  
Not 
admitted 
- - USA    
52 
Resolv
ed 
Ab def. 
CVID 
35-44 F - Antibiotics X X X      
Not 
admitted 
- - 
The 
Neth
erlan
ds 
Yes  35 days 
53 
Resolv
ed 
Ab def. 
CVID, 
(NFKB1) 
35-44 M 
Chronic 
diarrhea 
Ig X X  X  
Dyspnea, 
fatigue 
  
Hospital 
admission 
- 
Antibiotics, 
chloroquine, 
enoxaparin 
USA    
54 
Resolv
ed 
Ab def. 
XLA 
(BTK) 
35-44 M - Ig X X       
Hospital 
admission 
- 
Antibiotics, 
chloroquine, 
lopinavir, 
ritonavir 
Italy  6-14 days    
55 
Resolv
ed 
Ab def. 
CVID 
35-44 F Lung disease Ig  X       
Not 
admitted 
- Antibiotics 
Spai
n 
No 6-38 days 14 days 
56 
Resolv
ed 
Ab def. 
CVID 
35-44 F Lung disease Ig, antibiotics X X X  X 
Dyspnea, 
chest 
pain 
  
Hospital 
admission 
- 
Steroids, 
chloroquine 
Brazil    
57 
Resolv
ed 
Ab def. 
XLA 
(BTK) 
45-54 M 
Lung disease, 
liver disease, 
chronic skin 
and eye 
conditions 
Ig      
Asympto
matic 
  
Asympto
matic 
- - 
Spai
n 
   
58 
Resolv
ed 
Ab def. 
XLA 
(BTK) 
45-54 M 
Lung disease, 
liver disease 
Antibiotics, Ig X   X  
Campylob
acter 
jejuni co-
infection 
  
Hospital 
admission 
- - 
Spai
n 
   
59 
At 
home 
Ab def. 
CVID 
45-54 M 
Lung disease, 
kidney 
disease, GI 
disease 
Ig, steroids, 
mAb 
X        
Not 
admitted 
- - NA    
60 
Resolv
ed 
Ab def. 
CVID, 
(NFKB1) 
55-64 F 
Severe 
anemia 
Ig X X  X  
Dyspnea, 
fatigue 
  
Hospital 
admission 
- 
Antibiotics, 
chloroquine, 
enoxaparin 
USA    
61 
Resolv
ed 
Ab def. 
CVID 
55-64 M 
Lung disease, 
lymphoprolifer
Ig X  X  X    
Not 
admitted 
- Chloroquine 
Spai
n 
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ative disease 
62 
Resolv
ed 
Ab def. 
CVID 
55-64 M 
Lung disease, 
hypertension, 
splenomegaly 
and 
lymphadenop
athy 
Ig X        
Hospital 
admission 
- 
Chloroquine, 
ivermectin, 
anakinra 
Germ
any 
Yes 
(IgM) 29 days 6 weeks 
63 
Resolv
ed 
Ab def. 
CVID 
55-64 F Liver disease Ig  X       
Not 
admitted 
- - 
Germ
any 
No 58 days 2 weeks 
64 
Resolv
ed 
Ab def. 
AR 
agamma-
globuline
mia 
55-64 M Lung disease Ig      
Asympto
matic 
  
Asympto
matic 
- - Italy No 7 days  
65 
Resolv
ed 
Ab def 
Hypo-
gamma-
globuline
mia 
65-74 F 
Aortic 
coarctation 
Ig X X X X X    
Not 
admitted 
- - 
Fran
ce 
   
66 
Resolv
ed 
Ab def. 
CVID 
65-74 F 
Diabetes, 
hyper-tension, 
obesity 
Antibiotics X   X     
Not 
admitted 
- Antibiotics 
Fran
ce 
   
67 
Resolv
ed 
Ab def. 
CVID 
65-74 F - Ig, antibiotics X X    Dyspnea   
Hospital 
admission 
- 
Antibiotics, 
chloroquine, 
enoxaparin, 
conv. plasma 
USA    
68 
At 
home 
Ab def. 
CVID 
65-74 F - -  X   X Fatigue   
Not 
admitted 
- - USA No >1 month >1 month 
69 
Resolv
ed 
Ab def. 
CVID 
65-74 F 
Diabetes, 
obesity, 
hypertension 
Antibiotics X   X X Fatigue   
Not 
admitted 
- - 
Fran
ce 
No  2 days 
70 
Resolv
ed 
Ab def. 
IgG 
deficiency 
≥75 M - Ig X X    Dyspnea   
Not 
admitted 
- 
Antibiotics, 
chloroquine, 
enoxaparin 
USA    
71 
Resolv
ed 
Ab def 
Hypo-
gamma-
globuline
mia 
≥75 F 
Immune 
thrombocytop
enia, smoker, 
previous 
breast cancer 
Ig, 
antibiotics,AC
E inhibitor, 
simvastatin 
X X    
Infected 
during 
hospital 
admission 
for stroke 
  
Hospital 
admission 
- Antibiotics UK  15-24 days 15 days 
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72 
Resolv
ed 
CID 3-12 F - Antibiotics X   X X    
Hospital 
admission 
- 
Lopinavir, 
Ritonavir 
Spai
n 
No 6 days  
73 
Resolv
ed 
CID 
(ZAP70) 13-18 F 
Lung disease, 
diffuse large 
B-cell 
lymphoma 
Ig, rituximab, 
brentuximab 
X X X      
Hospital 
admission 
- - 
Fran
ce 
Yes 
36 days 
(still pos) 3 days 
74 
Resolv
ed 
CID 13-18 F Heart defect Antibiotics, Ig      
Asympto
matic 
  
Asympto
matic 
- - Chile    
75 
Resolv
ed 
CID 35-44 F 
AIHA, 
thrombocytop
enia, 
neutropenia, 
alopecia 
areata, 
recurrent 
HSV, 
splenomegaly 
Ig, antibiotics, 
antivirals, 
rituximab 
     
Anosmia, 
ageusia 
  
Not 
admitted 
- Antibiotics UK Yes  3 days 
76 
Resolv
ed 
CID 
(PGM3) 3-12 M 
Mental 
disability, 
neutropenia, 
eczema 
Antibiotics, 
antifungals, 
antivirals, G-
CSF 
X  X      
Not 
admitted 
- - USA    
77 
Resolv
ed 
CID 
Hyper IgE 
(STAT3) 
25-34 M 
Lung disease, 
hypertension 
Antibiotics, 
antifungals 
    X 
Headach
e 
  
Not 
admitted 
- - USA    
78 
Resolv
ed 
CID 
Hyper IgE 
(STAT3) 
35-44 M 
GI and skin 
disease 
Antibiotics  X    Anosmia   
Not 
admitted 
- - 
Spai
n 
Yes   
79 
Resolv
ed 
Auto-
inflammat
ion 
(MEFV) 
35-44 F Amyloidosis 
Canakinumab, 
colchicine 
X X X  X Dyspnea   
Not 
admitted 
- 
Steroids, 
chloroquine 
Brazil    
80 
Resolv
ed 
Auto-
inflammat
ion 
(MEFV) 
45-54 F Amyloidosis 
Canakinumab, 
colchicine 
X  X  X    
Not 
admitted 
- - Brazil    
81 
Resolv
ed 
Auto-
inflammat
ion 
AGS 
3-12 M 
Mental 
disability 
-      
Asympto
matic 
  
Asympto
matic 
- - 
Fran
ce 
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(RNASEH
2B) 
82 
Resolv
ed 
Auto-
inflammat
ion 
AGS 
(RNASEH
2B) 
3-12 M 
Mental 
disability 
-      
Asympto
matic 
  
Asympto
matic 
- - 
Fran
ce 
   
83 
Resolv
ed 
Auto-
inflammat
ion 
AGS 
(SAMHD1
) 
3-12 F 
Mental 
disability, 
spastic 
quadriplegy, 
epilepsy 
Sodium 
valproate, 
baclofen 
     
Rash on 
cheeks 
and arms 
  
Not 
admitted 
- 
Antibiotics, 
aspirin 
UK Yes  15 days 
84 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
(PRKCD) 
3-12 M 
Autoimmunity, 
invasive 
infections 
Ig, sirolimus, 
antibiotics, 
hydroxychloro
quine 
X X    
Rhinoviru
s co-
infection 
  
Hospital 
admission 
- Antibiotics UK    
85 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
Somatic 
ALPS 
3-12 F - Sirolimus      
Asympto
matic 
  
Asympto
matic 
- - 
Fran
ce 
Yes 
42 days 
(still pos) 28 days 
86 
Resolv
ed 
Immune 
dysregula
tion 
disorder 
(LRBA) 
19-24 M Diabetes 
Abatacept, Ig, 
insulin 
X X X      
Hospital 
admission 
- Antibiotics 
Fran
ce 
   
87 
Resolv
ed 
Immune 
dysregula
tion 
APECED 
(AIRE) 
19-24 M 
Lung 
diseases, 
diabetes, 
adrenal and 
thyroid 
insufficiency, 
heart disease, 
exocrine 
pancreatic 
insufficiency, 
functional 
Antibiotics, 
antifungals, 
insulin, 
adrenal and 
thyroid 
hormones 
X    X    
Hospital 
admission 
- Antibiotics 
Fran
ce 
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asplenia 
88 
Resolv
ed 
Phagocyt
e defects 
CGD 
(CYBB) 
3-12 M 
Hyporegenera
tive anemia 
Cyclosporine, 
antibiotics 
X  X      
Hospital 
admission 
- Antibiotics 
Fran
ce 
 <1 month  
89 
Resolv
ed 
Phagocyt
e defects 
CGD 
(NCF2) 
3-12 F Lung disease 
Antibiotics, 
antifungal 
     
Asympto
matic 
  
Asympto
matic 
- - UK    
90 
At 
home 
Phagocyt
e defects 
25-34 M Lung disease -  X       
Not 
admitted 
- - USA    
91 
Still in 
hospital 
Phagocyt
e defects 
35-44 M - 
Antibiotics, 
antifungals, 
mAb 
X  X   Fatigue   
Hospital 
admission 
- Chloroquine 
Spai
n 
   
92 
Resolv
ed 
Phagocyt
e defects 
CGD 
(CYBB) 
45-54 M Lung disease Antibiotics      Anosmia   
Not 
admitted 
- Antibiotics 
Mexi
co 
Yes   
93 
Resolv
ed 
STAT1 
GOF 
03-12 F Lung disease Ig      
Asympto
matic 
  
Asympto
matic 
- - Chile 
Yes 
(IgM)  21 days 
94 
Resolv
ed 
GATA2 
deficiency 
13-18 F 
Lung disease, 
bone marrow 
hypoplasia, 
pancytopenia 
Ig, steroids, 
antifungals, G-
CSF  
X   X  
Lower 
limbs 
edema, 
skin rash, 
hypotensi
on 
  
Hospital 
admission 
- 
Antibiotics, 
steroids, Ig 
Chile    
Ab def.: antibody deficiency; AGS: Aicardi-Goutiere syndrome; AI: autoimmune; AIHA: autoimmune hemolytic anemia; ALPS: autoimmune lymphoproliferative syndrome; CID: 3 
combined immunodeficiency; CGD: chronic granulomatous disease; conv.: convalescent; CVID: common variable immunodeficiency; def: deficiency; ECMO: extracorporeal 4 
membrane oxygenation; F: female; GI: gastrointestinal; GM-CSF: granulocyte-monocyte colony stimulating factor; GVHD: graft vs host disease; HLH: hemophagocytic 5 
lymphohistiocytosis; HSCT: hematopoietic stem cell transplantation; IBD: inflammatory bowel disease; ICU: intensive care unit; Ig: immunoglobulins; ITP: immune 6 
thrombocytopenia; JCV: JC virus; M: male; mAb: monoclonal antibody; MSMD: Mendelian susceptibility to mycobacterial disease; O2: oxygen; NA: not available; NIV: non-7 
invasive ventilation; PID: primary immunodeficiency; pos: positive; Pt. n.: patient number; syndr: syndrome; URS: upper respiratory symptoms; XLA: X-linked 8 
agammaglobulinemia. Choroquine and hydroxychloroquine are considered a single treatment group. 9 
 10 
Jo
urn
al 
Pr
e-p
roo
f
Jo
urn
al 
Pr
e-p
roo
f
